ArticleResearch square2026
A Clinically Grounded Rule-Based Phenotyping Framework for Identifying Immune-Related Adverse Events in Structured Electronic Health Record Data: A Retrospective EHR Study.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Accurate identification of immune-related adverse events (irAEs) in structured electronic health record (EHR) data remains a major challenge due to the lack of specific diagnostic codes and inconsistent documentation. We propose a clinically grounded, generalizable framework for phenotyping irAEs in structured data, using immune-mediated diarrhea and colitis (IMDC) as a representative use case. Methods: Using a large, curated EHR-derived dataset of adults with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs), we developed a rule-based phenotyping framework informed by clinical practice guidelines and the clinical course of irAEs. The approach integrates (1) treatment exposure, (2) temporally anchored immunosuppressive therapy, and (3) diagnostic code patterns to identify moderate-to-severe irAEs, with IMDC used to enhance specificity. Results: We developed and demonstrated a guideline-informed framework for identifying complex treatment-related toxicities in structured EHR data, using immune-mediated diarrhea and colitis (IMDC) as a representative use case. Among 14,659 eligible patients treated with immune checkpoint inhibitors, 576 (3.93%) met criteria for potential grade 2-4 immune-related adverse events (irAEs). Of these, 58 (0.40%) were further classified as IMDC based on temporally aligned diagnostic codes. The framework demonstrated the feasibility of identifying clinically meaningful adverse events using structured data elements and guideline-informed temporal relationships. Conclusions: This study presents a scalable, clinically interpretable, and generalizable framework for phenotyping complex clinical outcomes in structured EHR data without reliance on advanced computational methods. By leveraging treatment patterns, diagnostic codes, and guideline-informed temporal relationships, the approach enhances reproducibility and portability across datasets and healthcare settings. Clinically grounded, rule-based phenotyping may serve as a practical complement to machine learning and natural language processing approaches when developing computable phenotypes for complex treatment-related toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.